Promising combo for liver cancer stalls: trial ends early
NCT ID NCT04327700
First seen Mar 06, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This study aimed to see if adding electromagnetic fields to the drug regorafenib could help people with advanced liver cancer live longer without their cancer growing. Only 2 people joined before the study was stopped early. The treatment was for patients who had already tried other therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
Conditions
Explore the condition pages connected to this study.